DPP4 and myotonic dystrophy type 2: We conducted a pairwise meta-analysis and meta-regression of randomized clinical trials, including patients with DM2, comparing the risk of DR complications between new antidiabetic drugs sodium–glucose cotransporter-2 inhibitors (SGLT-2i), GLP-1RA, dipeptidyl peptidase-4 inhibitors (DPP-4i), and placebo.